Dr Shaji Kumar presents results at the 2019 European Hematology Association (EHA) Annual Meeting from a study looking at the addition of venetoclax to bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

The trial randomised patients between venetoclax or placebo with bortezomib and dexamethasone and although patients receiving venetoclax saw an improved response and progression-free survival, there was an increase in treatment-emergent deaths.